Reported 3 months ago
Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) are declining following Roche's (ROG.SW, RBO.PA) release of promising early-stage trial data for its weight-loss pill. The report discusses how the new medication could impact the weight-loss drug market dominated by GLP-1 drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, both experiencing high demand. For expert analysis and market updates, watch the full episode of Market Domination for more details.
Source: YAHOO